A rare extramedullary involvement in myeloma: lung parenchyma and association with unfavorable chromosomal abnormalities

被引:2
作者
Balcik, Ozlem Sahin [1 ]
Albayrak, Murat [1 ]
Dagdas, Simten [2 ]
Ceran, Funda [2 ]
Ozet, Gulsum [2 ]
Demirag, Funda [3 ]
Yokus, Osman [4 ]
机构
[1] Oncol Educ & Res Hosp, Dept Hematol, Ankara, Turkey
[2] Numune Educ & Res Hosp, Dept Hematol, Ankara, Turkey
[3] Ataturk Chest Dis & Chest Surg Educ & Res Hosp, Dept Pathol, Ankara, Turkey
[4] Kayseri Educ & Res Hosp, Dept Hematol, Kayseri, Turkey
关键词
Myeloma; pulmonary involvement; prognostication; cytogenetics; molecular genetics; del(13q); hypodiploidy; CENTRAL-NERVOUS-SYSTEM; PLASMA-CELL LEUKEMIA; MULTIPLE-MYELOMA; STAGING SYSTEM; FEATURES; HYPODIPLOIDY; PATIENT;
D O I
10.5152/tjh.2010.08
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although pulmonary complications developing secondary to lung infections and involvement in ribs occur frequently in multiple myeloma (MM), involvement of the lung parenchyma is quite rare. In clinical studies, the involvement of lung parenchyma has been found to be associated with unfavorable prognosis. Here, a MM case in whom involvement of lung parenchyma was accompanied by unfavorable prognostic cytogenetic markers is presented. A 62-year-old male presented with complaint of cough, and heterogeneous hypodense mass was detected in thorax computerized tomography. The patient underwent bronchoscopic biopsy. Pathological examination revealed diffuse plasma cell infiltration staining with kappa immunohistochemically. In bone marrow biopsy, plasma cell infiltration was observed. In conventional cytogenetic examination, hypodiploidy was established. In cytogenetic examination carried out with fluorescence in situ hybridization, deletion (13q) was determined. In conclusion, in patients diagnosed with MM and presenting with pulmonary mass lesion, lung involvement associated with plasma cell infiltration should also be considered in the differential diagnosis. As overall survival is low in these cases, more aggressive treatment approaches such as high-dose treatment should be immediately considered. (Turk J Hematol 2010; 27: 109-12)
引用
收藏
页码:109 / 112
页数:4
相关论文
共 23 条
[1]  
ABELMAN W, 1995, MODERN PATHOL, V8, P257
[2]   Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide a case report and review of the literature [J].
Alexandrescu, DT ;
Koulova, L ;
Wiernik, PH .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2005, 30 (04) :391-394
[3]  
[Anonymous], HEMATOLOGY BASIC PRI
[4]   Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions [J].
Chang, H ;
Sloan, S ;
Li, D ;
Stewart, AK .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :280-284
[5]   Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center [J].
Damaj, G ;
Mohty, M ;
Vey, N ;
Dincan, E ;
Bouabdallah, R ;
Faucher, C ;
Stoppa, AM ;
Gastaut, JA .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (06) :402-406
[6]  
DEWALD GW, 1985, BLOOD, V66, P380
[7]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[8]  
2-U
[9]   Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features [J].
Fassas, ABT ;
Ward, S ;
Muwalla, F ;
Van Hemert, R ;
Schluterman, K ;
Harik, S ;
Tricot, G .
LEUKEMIA & LYMPHOMA, 2004, 45 (02) :291-300
[10]   Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma [J].
Fassas, ABT ;
Spencer, T ;
Sawyer, J ;
Zangari, M ;
Lee, CK ;
Anaissie, E ;
Muwalla, F ;
Morris, C ;
Barlogie, B ;
Tricot, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) :1041-1047